| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal system disease | Under Development | Humans | 0.12 | KE:288 | Activation of specific nuclear receptors, Transcriptional change |
| AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | Pimephales promelas | 0.1 | KE:800 | Decreased, Aromatase (Cyp19a1) mRNA |
| AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | Pimephales promelas | 0.09 | KE:800 | Decreased, Aromatase (Cyp19a1) mRNA |
| AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.1 | KE:2165 | Activation of PPAR |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired metabolic disease | - | Mus musculus, Homo sapiens | 0.1 | KE:2129 | Metabolically unhealthy Obesity |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive system disease; Endocrine system disease; Reproductive system disease | Under Review | Rat, Mouse, Human | 0.2 | KE:408 | reduction in ovarian granulosa cells, Aromatase (Cyp19a1) |
| AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Medaka, Zebrafish | 0.12 | KE:36 | Inhibition, Aromatase |
| AOP:232 | NFE2/Nrf2 repression to steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.12 | KE:1417 | NFE2/Nrf2 repression | |
| AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Oreochromis niloticus, Chinook salmon, Fathead minnow, European sea bass | 0.2 | KE:36 | Inhibition, Aromatase |
| AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.17 | KE:1417 | NFE2/Nrf2 repression |
| AOP:508 | Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.14 | KE:1417 | NFE2/Nrf2 repression |
| AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular system disease | - | 0.14 | KE:1417 | NFE2/Nrf2 repression | |
| AOP:549 | Aromatase inhibition leads to reproductive toxicity (including growth and developmental toxicity) in adult female zebrafish | Unclassified | - | 0.12 | KE:36 | Inhibition, Aromatase |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.